CD274 and non-small cell lung carcinoma: As PD-1 blockade may promote tumor growth in NSCLC and possibly other cancers, it may be plausible to apply anti-PD-L1 instead of anti-PD-1 for checkpoint blockade, or to combine antiproliferative drugs with anti-PD-1 therapy.